【诺和诺德:Q1销售额780.9亿丹麦克朗,低于预期】诺和诺德公布一季度财报显示: 销售额780.9亿丹麦克朗,预估787亿丹麦克朗。 EBIT 387.9亿丹麦克朗,预估371.2亿丹麦克朗。 净利润290.3亿丹麦克朗,预估279.1亿丹麦克朗。 税前利润370.3亿丹麦克朗,预估352.6亿丹麦克朗。 减肥药Wegovy销售额173.6亿丹麦克朗,预估189.8亿丹麦克朗。 Ozempic销售额327.2亿丹麦克朗,预估323.2亿丹麦克朗。 诺和诺德预计在固定汇率下,全年销售额将增长13%-21%,市场预估增长18.6%,此前预估增长16%-24%;全年运营利润增长16%-24%,市场预估增长22.4%,此前预计增长19%-27%。

金融界
07 May
诺和诺德公布一季度财报显示: 销售额780.9亿丹麦克朗,预估787亿丹麦克朗。 EBIT 387.9亿丹麦克朗,预估371.2亿丹麦克朗。 净利润290.3亿丹麦克朗,预估279.1亿丹麦克朗。 税前利润370.3亿丹麦克朗,预估352.6亿丹麦克朗。 减肥药Wegovy销售额173.6亿丹麦克朗,预估189.8亿丹麦克朗。 Ozempic销售额327.2亿丹麦克朗,预估323.2亿丹麦克朗。 诺和诺德预计在固定汇率下,全年销售额将增长13%-21%,市场预估增长18.6%,此前预估增长16%-24%;全年运营利润增长16%-24%,市场预估增长22.4%,此前预计增长19%-27%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10